I am a transplant hepatologist and the medical director of living donor liver transplant at NewYork-Presbyterian Hospital.

Garnik Arustamyan is an undergraduate student at the University of Southern California pursuing a Bachelor of Science in Health Promotion and Disease Prevention Studies with a minor in Health Care Studies. His academic interests include gastroenterology and hepatology, with a particular focus on understanding the mechanisms of liver disease and advancing bench-to-bedside translation of scientific research.

I am a research faculty at Northwestern University Feinberg School of Medicine. My research goal is to identity new targets for therapeutic intervention for liver injury and fibrosis, with a focus on MAFLD/MASH and cholestatic liver diseases. I am particularly interested in the role of the unfolded protein response (UPR), an ER stress-induced adaptive response, in the pathogenesis of liver diseases.

I am a transplant hepatologist at Intermountain Medical Center in Utah. My research interests include genetic causes of liver disease and bioengineered liver support devices.

I am Islam B. Mohamed, MD, MSc, a hepatology clinical fellow at the NIH/NIDDK, with prior training in hepatology and liver transplantation at Ain Shams University, Cairo, Egypt, and research experience at Baylor College of Medicine. At Baylor, I contributed to clinical research investigating the role of microbiome-based therapy for severe alcohol-associated hepatitis, socioeconomic disparities in access to liver transplantation, and predictors of alcohol relapse following transplant evaluation.

Atsushi Nishimagi, MD, PhD is a Research Lab Associate II in the Division of Transplant and Hepatobiliary Surgery at Henry Ford Hospital in Detroit, Michigan.
His clinical research focuses on liver transplantation, particularly on novel preservation techniques such as Normothermic Machine Perfusion (NMP) and Normothermic Regional Perfusion (NRP) to improve graft function and expand the donor pool.

Alberto Sanchez-Fueyo is Professor of Hepatology at King's College London University and founder of Quell Therapeutics Ltd. His research is focused in understanding the mechanisms of transplantation tolerance in the clinic and developing novel immunotherapeutic strategies.

Sarpong Boateng, MD, MPH is the 2025 AASLD Raymond T. Chung Emerging Liver Scholar